image
Healthcare - Biotechnology - NASDAQ - US
$ 1.91
31.7 %
$ 239 M
Market Cap
-1.26
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VOR stock under the worst case scenario is HIDDEN Compared to the current market price of 1.91 USD, Vor Biopharma Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VOR stock under the base case scenario is HIDDEN Compared to the current market price of 1.91 USD, Vor Biopharma Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VOR stock under the best case scenario is HIDDEN Compared to the current market price of 1.91 USD, Vor Biopharma Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VOR

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6$0.4$0.4$0.2$0.2$0.0$0.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-121 M OPERATING INCOME
3.85%
-117 M NET INCOME
0.81%
-99.7 M OPERATING CASH FLOW
0.63%
96.9 M INVESTING CASH FLOW
36.40%
53.4 M FINANCING CASH FLOW
1717.29%
0 REVENUE
0.00%
-33.3 M OPERATING INCOME
-6.32%
-32.5 M NET INCOME
-5.78%
-31.1 M OPERATING CASH FLOW
-29.10%
-230 K INVESTING CASH FLOW
-219.44%
-606 K FINANCING CASH FLOW
-1.14%
Balance Sheet Vor Biopharma Inc.
image
Current Assets 96.5 M
Cash & Short-Term Investments 91.9 M
Receivables 0
Other Current Assets 4.58 M
Non-Current Assets 46.4 M
Long-Term Investments 0
PP&E 41.6 M
Other Non-Current Assets 4.8 M
64.33 %3.21 %29.10 %3.36 %Total Assets$142.9m
Current Liabilities 18.6 M
Accounts Payable 1.5 M
Short-Term Debt 8.43 M
Other Current Liabilities 8.68 M
Non-Current Liabilities 27.6 M
Long-Term Debt 27.6 M
Other Non-Current Liabilities 0
3.26 %18.24 %18.77 %59.74 %Total Liabilities$46.2m
EFFICIENCY
Earnings Waterfall Vor Biopharma Inc.
image
Revenue 0
Cost Of Revenue 3.53 M
Gross Profit 0
Operating Expenses 121 M
Operating Income -121 M
Other Expenses -4.27 M
Net Income -117 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)0(4m)0(121m)(121m)4m(117m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-120.95% ROE
-120.95%
-81.82% ROA
-81.82%
-91.32% ROIC
-91.32%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vor Biopharma Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20192019202020202021202120222022202320232024202420252025
Net Income -117 M
Depreciation & Amortization 3.53 M
Capital Expenditures -229 K
Stock-Based Compensation 9.85 M
Change in Working Capital 5 K
Others 1.64 M
Free Cash Flow -99.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vor Biopharma Inc.
image
Wall Street analysts predict an average 1-year price target for VOR of $3 , with forecasts ranging from a low of $3 to a high of $3 .
VOR Lowest Price Target Wall Street Target
3 USD 57.07%
VOR Average Price Target Wall Street Target
3 USD 57.07%
VOR Highest Price Target Wall Street Target
3 USD 57.07%
Price
Max Price Target
Min Price Target
Average Price Target
33332222111100Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Vor Biopharma Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
6.66 K USD 1
6-9 MONTHS
12.9 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
79.6 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company's Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio's common stock in connection with the commencement of his employment. The foregoing stock option was granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). globenewswire.com - 5 days ago
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market H.C. Wainwright upgraded Vor Biopharma Inc. VOR, highlighting the company's “rebirth” following the in-licensing of telitacicept. benzinga.com - 6 days ago
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman. zacks.com - 6 days ago
Vor Bio Announces $175 Million Private Placement CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses. globenewswire.com - 1 week ago
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset -Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties -Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio, Inc. (Nasdaq: VOR) and RemeGen Co., Ltd. globenewswire.com - 1 week ago
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value. globenewswire.com - 1 month ago
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update. globenewswire.com - 3 months ago
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials. globenewswire.com - 4 months ago
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference. globenewswire.com - 5 months ago
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. zacks.com - 5 months ago
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund. globenewswire.com - 5 months ago
Vor Bio Announces $55.6 Million Private Placement Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 globenewswire.com - 6 months ago
8. Profile Summary

Vor Biopharma Inc. VOR

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 239 M
Dividend Yield 0.00%
Description Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Contact 100 Cambridgepark Drive, Cambridge, MA, 02140 https://www.vorbio.com
IPO Date Feb. 5, 2021
Employees 159
Officers Ms. Tania Philipp Chief People Officer Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. Scientific Founder & Chairman of Scientific Advisory Board Mr. David Phillips M.B.A. Senior Vice President & Head of Quality Dr. Robert Ang M.B.A., M.D., MBBS President, Chief Executive Officer & Director Ms. Amy Quinlan Interim Principal Accounting Officer